Achieve Life Sciences Inc
NASDAQ:ACHV

Watchlist Manager
Achieve Life Sciences Inc Logo
Achieve Life Sciences Inc
NASDAQ:ACHV
Watchlist
Price: 3.69 USD -3.4%
Market Cap: 126.7m USD
Have any thoughts about
Achieve Life Sciences Inc?
Write Note

Achieve Life Sciences Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Achieve Life Sciences Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Achieve Life Sciences Inc
NASDAQ:ACHV
Operating Income
-$31.3m
CAGR 3-Years
-1%
CAGR 5-Years
-13%
CAGR 10-Years
0%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%
No Stocks Found

Achieve Life Sciences Inc
Glance View

Market Cap
126.9m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
5.1 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Achieve Life Sciences Inc's Operating Income?
Operating Income
-31.3m USD

Based on the financial report for Sep 30, 2024, Achieve Life Sciences Inc's Operating Income amounts to -31.3m USD.

What is Achieve Life Sciences Inc's Operating Income growth rate?
Operating Income CAGR 10Y
0%

Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for Achieve Life Sciences Inc have been -1% over the past three years , -13% over the past five years .

Back to Top